Updated · The Transmitter: Neuroscience News and Perspectives · Jun 3
Yale Brain Shuttle Shows Mouse Gains Under $40 Million NIH Grant as Mechanism and Conflicts Draw Scrutiny
Updated
Updated · The Transmitter: Neuroscience News and Perspectives · Jun 3
Yale Brain Shuttle Shows Mouse Gains Under $40 Million NIH Grant as Mechanism and Conflicts Draw Scrutiny
1 articles · Updated · The Transmitter: Neuroscience News and Perspectives · Jun 3
Summary
A November 2025 preprint showed Yale’s STEP-RNPs spread gene-editing cargo across mouse brains and improved learning, motor function and seizure activity in Angelman syndrome models.
The technology packages Cas9 ribonucleoproteins into a roughly 10-nanometer carrier—about half an AAV’s size—and researchers say it may avoid some viral-delivery limits, though they still cannot fully explain how it enters cells.
No peer-reviewed paper has yet detailed the platform, and the preprint did not show side-by-side comparisons with AAVs or evidence that STEP crosses the blood-brain barrier, leaving outside scientists cautious about whether mouse results will scale to primates or humans.
Yale won the largest 2023 SCGE award—$40 million, including $15 million for early clinical work—and has begun nonhuman-primate testing, with fuller data required to be shared through the NIH program by 2028.
The project also raises conflict questions because Yale licensed STEP to startup Couragene, in which Jiang holds equity, while the university does not publicly release its conflict-management plan.
Yale's secret gene therapy shows promise for brain diseases, but can it deliver a cure without causing devastating genomic damage?
A $40M public grant spawned a private company for a new brain therapy. Will this cure reach the patients who need it most?
Yale’s STEP Technology and the $40 Million NIH Bet: The Future and Risks of Brain Gene Editing
Overview
Yale University has received a $40 million NIH grant to develop a new way to deliver gene-editing tools into the brain, aiming to overcome major challenges in treating neurogenetic diseases. This work focuses on creating a delivery platform that can safely and effectively reach brain cells, which is crucial for addressing serious neurological disorders. If successful, the technology could inspire other labs to adopt similar methods. Yale is required to publicly share its progress by 2028, which is expected to provide valuable insights and encourage further research in brain-targeted gene editing.